Leadership and board of directors
Our leadership team spans cell production, clinical development, regulatory affairs, patient advocacy and capital markets, and is supported by a scientific advisory board of ALS and MS clinicians.
Executive team
- Peter J. PittsExecutive Chairman and Chief Strategic Regulatory and Policy Officer
- Chaim LebovitsPresident, Chief Executive Officer
- Haro Hartounian, PhDExecutive Vice President, Chief Operating Officer
- Uri Yablonka, LL.MExecutive Vice President, Chief Business Officer
- Mary Kay TurnerSenior Vice President, Patient Advocacy and Government Affairs
- Netta Blondheim-Shraga, PhDSenior Vice President, Research and Development
- Yossef Levy, PhDVice President, Cell Production
- Alla Patlis, CPA, MBAInterim Chief Financial Officer
Board of directors
The board is chaired by the Executive Chairman and meets the independence and committee requirements set out in our corporate governance documents.
Scientific advisory board
Clinicians and researchers in ALS and multiple sclerosis who advise on the program. They are advisers to the company, not officers or directors of it.